Catalyst Capital Advisors’s Exagen XGN Stock Holding History

Catalyst Capital Advisors’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-329	Closed	-$5K	–	424
2019 Q3	$5K	Buy	+329	New	+$5.31K	﹤0.01%	403

Other funds holding XGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Catalyst Capital Advisors's XGN Position: Q4 2019 in Review

Catalyst Capital Advisors sold out of Exagen (XGN) in Q4 2019, closing a stake of 329 shares — an estimated $5K sold.

Catalyst Capital Advisors first reported a position in XGN in Q3 2019 and held it in 1 quarter. The position peaked at $5K in Q3 2019. 36 funds tracked by Wall St. Rank hold XGN as of Q4 2019.

Catalyst Capital Advisors reported no remaining Exagen position as of Q4 2019 after selling out during the quarter.
Catalyst Capital Advisors sold 329 Exagen shares in Q4 2019, an estimated $5K.
Catalyst Capital Advisors first reported a position in Exagen in Q3 2019 and held it in 1 quarter.
Catalyst Capital Advisors's Exagen position peaked at $5K in Q3 2019.
36 funds tracked by Wall St. Rank held Exagen as of Q4 2019.

Based on Catalyst Capital Advisors's 13F filing for Q4 2019, filed 6 Feb 2020.